Lonza is advancing its leading GS Gene Expression System® with the next-generation GS Ori-Go® vector technology designed to support the increasing complexity of multi-specific and novel therapeutic formats. Through enhanced glutamine synthetase regulation and greater selection stringency, this innovative platform increases titers, delivers robust expression stability, simplifies workflows, and accelerates cell line development timelines, helping enable faster and more efficient biotherapeutic development.
You may also be interested in:
Expression Technologies
Difficult to Express Proteins
Monoclonal Antibody
Cell Line Development
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.
Latest briefing from the Knowledge Center
Poster
GS Ori-Go®: Next-generation CHO expression vectors for enhanced productivity, stability and speed
Lonza is advancing its leading GS Gene Expression System® with the next-generation GS Ori-Go® vector...
Article
Manufacturability and Developability Assessment as the Technical Foundation of a Strong Biologic...
In this article, our expert Michael Hodskinson, Ph.D., discusses why manufacturability and...
Article
Early Protein Expression Assessment and the Value of Starting in a Proven System
In this article our experts discuss the role of early protein expression assessment as a critical...
White paper
Overcoming the Obstacles of Spray-Dried Dispersion Scale-Up
As poorly soluble small-molecule drug candidates continue to challenge development timelines, the...
Article
Early-Stage Biotech Success Starts with the Right Development and Manufacturing Partner
Article
The Specifics of Speed: How to Reach the Clinic Faster While Maintaining Precision
How can mAb programs reach the clinic in as little as six months without increasing CMC risk? Are...
Webinar (on-demand)
Transitioning to AAV Producer Cell Lines: Navigating Comparability, Bridging Studies, and Regulatory...
As AAV-based gene therapies continue to advance toward broader indications, manufacturing...
Article
From Discovery to Delivery: Why Collaboration Is Essential to Advancing Tomorrow's Therapies
The pace of innovation in biotechnology has never been greater. Advances in areas such as precision...
Technical/Service brief
Lonza Early Development Services Brochure
Developing a biologic candidate for clinical studies requires early identification of potential...
Webinar (on-demand)
Building Scalable Non-Viral Gene-Editing Cell Therapies
Achieving strong gene editing results is only the first step toward successful non-viral cell...
White paper
In vivo CAR-T Strategic Market Update and Manufacturing Implications for CDMO Partners
In vivo CAR-T has become a strategic priority for large biopharma. Between 2025 and early 2026, the...
White paper
Automated, Scalable, and GMP-compliant MSC Cell Therapy and EV Manufacturing Using Lonza TheraPEAK®...
Discover a practical approach to mesenchymal stem cell (MSC) and extracellular vesicle (EV)...